Myelofibrosis Cancer Studies Currently Recruiting Participants at the University of Chicago Cancer Research Center

Study Number	Title
10-064-B	Molecular characterization of hematopoietic malignancies
11-0619	An open label assessment of safety and efficacy of Ruxolitinib (INCB018424) in subjects with primary myelofibrosis, post essential thrombocythemia-myelofibrosis and post polycythemia vera-myelofibrosis who have platelet counts of 50 x109/L to 100 x109/L.

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.